XML 64 R47.htm IDEA: XBRL DOCUMENT v3.25.0.1
Business Combination - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended 12 Months Ended
May 24, 2022
Jun. 30, 2023
Dec. 31, 2022
Business Acquisition [Line Items]      
Adjustment, accounts receivable, net   $ 200  
Antares Pharma, Inc      
Business Acquisition [Line Items]      
Purchase consideration $ 1,045,668    
Consideration transferred, cash paid per acquiree share (usd per share) $ 5.60    
Consideration related to acquiree closing indebtedness settled $ 19,683    
Consideration for seller transaction costs paid by Halozyme 22,906    
Transaction costs     $ 21,900
Adjustment, accrued expenses   2,000  
Adjustments, deferred tax liabilities, net   $ 5,500  
Pro forma revenue of acquiree since acquisition date     112,700
Proforma net loss of acquiree since acquisition date     $ 67,600
Antares Pharma, Inc | Revolving Credit Facility      
Business Acquisition [Line Items]      
Credit facility, maximum borrowing capacity 350,000    
Antares Pharma, Inc | Term Loan Facility      
Business Acquisition [Line Items]      
Credit facility, maximum borrowing capacity $ 250,000